2023 Outlook
In 2023, Valneva expects further product sales growth as the travel market continues to recover.
Our Financials & Outlook
2023 Financial Guidance
- Expected total revenues and other income between €220 million and €260 million:
-
- €130 million to €150 million of product sales, including marginal COVID-19 vaccine sales under an existing supply agreement with the Kingdom of Bahrain
- Between €90 million and €110 million of other income
- R&D expenses expected between €70 million and €90 million